All Pharmaceutical Microbiology articles – Page 4
-
NewsPhase I study for human monoclonal antibody for Lyme disease demonstrates safety, tolerability, pharmacokinetics
A Phase I clinical trial of a human monoclonal antibody discovered and developed for the prevention of Lyme disease in the U.S. was well tolerated and showed lasting serum concentrations in participants, according to data.
-
NewsShiitake-derived β-glucan inhibits human cervical cancer progression through DMBT1
A team of researchers investigated the molecular mechanism underlying the anti-cervical cancer activity of Lentinus edodes-derived β-glucan (LNT) and, for the first time, identified DMBT1 as a key target.
-
NewsVanderbilt Center for Antibody Therapeutics signs agreement to develop anti-measles antibody treatment
The Vanderbilt Center for Antibody Therapeutics has signed an option agreement with Saravir Biopharma Inc. for the company to develop human monoclonal antibodies isolated in the laboratory of James Crowe Jr., MD, for the treatment and prevention of measles.
-
NewsInterferon therapy found to be well-tolerated in compensated hepatitis B cirrhosis
A multicenter analysis of 920 patients finds no higher risk of serious complications in compensated cirrhosis compared to standard treatment.
-
NewsVirus-inspired DNA needle could pave the way for better medicines
Researchers have developed a microscopic DNA needle that delivers molecules directly into cells and helps keep them active. It may solve a major problem in modern medicine: many therapies are trapped inside cells and lose their effect.
-
NewsThesis confirms algae have strong wound-healing, skin-protective, and immune-supporting properties
New research demonstrates that polysaccharides extracted from various seaweeds and freshwater cyanobacteria possess remarkable bioactive properties and can accelerate wound healing, reduce inflammation, and protect skin cells from UV-induced damage.
-
NewsA natural molecule present in the human body protects against the flu
A research team has demonstrated that dermcidin, an antimicrobial peptide produced constitutively by the human body, also exhibits antiviral activity against the influenza virus. People who do not develop flu-like symptoms have higher baseline levels of this molecule.
-
NewsCopper-loaded starch nanoparticles can target bacteria in microbial communities
Researchers have developed copper-loaded starch nanoparticles that can be broken down by specific bacteria to release antibacterial copper molecules. They hope that these nanoparticles can be used to target biofilms, which account for 50-70% of healthcare-associated infections.
-
NewsStudy reveals how a live bacterial therapy reshapes the vaginal microbiome and identifies predictors of treatment success
A new study provides the most detailed picture yet of how a promising bacterial therapy works to prevent recurrent bacterial vaginosis (BV) and why it works better for some women than others.
-
NewsNew flu drug discovery could help fight future pandemics
Scientists say that new laboratory tests have revealed a new way to stop flu viruses, which could lead to better treatments and improved pandemic preparedness. The international team has developed experimental compounds that appear to block the virus more effectively than current medicines.
-
NewsSimple antiseptic can reduce newborn infections
A new Cochrane review finds that chlorhexidine likely cuts umbilical cord infection rates by about 29% in low- and middle-income countries, and may reduce newborn deaths.
-
NewsCancer drug repurposed to treat drug-resistant herpes
Researchers have successfully repurposed an FDA-approved cancer drug, doxorubicin, to treat drug-resistant strains of herpes. A digital tool that combs through chemical compounds and flags those that may be effective against herpes infections, identified doxorubicin, a known anticancer drug.
-
NewsMachine learning identifies antimicrobial peptide candidate for ulcerative colitis
Scientists applied machine learning to accelerate AMP discovery and identify candidates with therapeutic potential for ulcerative colitis.
-
NewsWhy some people naturally control HIV even after stopping therapy — and how we can leverage that to treat others
New research offers a path toward life without daily HIV pills, suggesting a common diabetes pill could help achieve long-term remission.
-
NewsPromising active substance against hepatitis E identified
A drug that is already in clinical trials against hepatitis C virus can also prevent hepatitis E virus from replicating An international research team has filtered bemnifosbuvir, a nucleotide/nucleoside analogue, out of a library of active substances.
-
NewsTarget behind cancer drug shown to help fight influenza in mice
A protein already targeted by FDA-approved cancer drugs may also help the body fight influenza. A study found that Programmed Death-Ligand 1 (PD-L1), best known for helping tumors evade immune attack, instead helped immunocompromised mice clear flu-infected lung cells and survive infection.
-
NewsNew drug candidate extremely effective against H. pylori bacterium
Researchers have discovered that metronidazole targets two central protective proteins of Helicobacter pylori: an enzyme responsible for detoxifying harmful reactive oxygen species and a protein that repairs damaged proteins.
-
NewsEngineered bacteria deliver cancer drug directly inside tumors in mice
New research suggests that Escherichia coli Nissle 1917 (EcN) may be engineered with anticancer agents to treat cancerous tumors in mice. Researchers used EcN as a base for synthesizing Romidepsin (FK228), an FDA-approved drug with anti-tumor agents.
-
NewsScientists reveal valuable secrets of Pacific coral reefs
An international consortium of scientists has uncovered new insights into coral ecosystems, revealing that different coral species host their own distinct communities of microbes. They show that coral reefs harbour diverse microbes and produce chemicals with promising potential.
-
NewsPlastic bottles transformed into Parkinson’s drug using bacteria
A drug to treat Parkinson’s disease can be made from waste plastic bottles using a pioneering method. The approach harnesses the power of bacteria to transform post-consumer plastic into L-DOPA, a frontline medication for the neurological disorder.